<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endofocus</journal-id><journal-title-group><journal-title xml:lang="ru">FOCUS Эндокринология</journal-title><trans-title-group xml:lang="en"><trans-title>FOCUS. Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-0177</issn><issn pub-type="epub">2713-0185</issn><publisher><publisher-name>ООО "Издательство "Перо"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.62751/2713-0177-2025-6-1-01</article-id><article-id custom-type="elpub" pub-id-type="custom">endofocus-96</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Метаболический синдром при сахарном диабете 1 типа у взрослых</article-title><trans-title-group xml:lang="en"><trans-title>Metabolic syndrome in type 1 diabetes mellitus in adults</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9841-0611</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малиевская</surname><given-names>Р. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Malievskaya</surname><given-names>R. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Малиевская Рамзия Илюсовна – ассистент кафедры эндокринологии</p><p>Scopus Author ID: 58922537100</p><p>г. Уфа</p></bio><bio xml:lang="en"><p>Ramsiya I. Malievskaya – MD, assistant professor</p><p>Scopus Author ID: 5892253710</p><p>Ufa</p></bio><email xlink:type="simple">ramsiya1987@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1590-6433</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авзалетдинова</surname><given-names>Д. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Avzaletdinova</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Авзалетдинова Диана Шамилевна – д.м.н., доцент кафедры эндокринологии</p><p>Scopus Author ID: 8317662600</p><p>г. Уфа</p></bio><bio xml:lang="en"><p>Diana S. Avzaletdinova – MD, PhD, associate professor</p><p>Scopus Author ID: 8317662600</p><p>Ufa</p></bio><email xlink:type="simple">hyppocrat@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-6565-6736</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насретдинова</surname><given-names>Ю. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasretdinova</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Насретдинова Юлия Георгиевна – ординатор кафедры эндокринологии</p><p>г. Уфа</p></bio><bio xml:lang="en"><p>Yulia G. Nasretdinova – resident of the Department of endocrinology</p><p>Ufa</p></bio><email xlink:type="simple">y.nasretdinova@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-9920-4245</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Урманова</surname><given-names>И. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Urmanova</surname><given-names>I. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Урманова Индира Зуфаровна – врач-эндокринолог</p><p>г. Арск</p></bio><bio xml:lang="en"><p>Indira Z. Urmanova – endocrinologist</p><p>Arsk</p></bio><email xlink:type="simple">urmanova.indira@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-1352-987X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иксанова</surname><given-names>Д. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Iksanova</surname><given-names>D. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иксанова Динара Фаритовна – врач-эндокринолог</p><p>г. Уфа</p></bio><bio xml:lang="en"><p>Dinara F. Iksanova – endocrinologist</p><p>Ufa</p></bio><email xlink:type="simple">dinaraiksanova1996@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России</institution></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГАУЗ «Арская центральная районная больница»</institution></aff><aff xml:lang="en"><institution>Arsk Central District Hospital</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ РБ «Городская клиническая больница №5»</institution></aff><aff xml:lang="en"><institution>City Clinical Hospital № 5</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>05</month><year>2025</year></pub-date><volume>6</volume><issue>1</issue><issue-title>Коморбидность в эндокринологии</issue-title><fpage>6</fpage><lpage>12</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Малиевская Р.И., Авзалетдинова Д.Ш., Насретдинова Ю.Г., Урманова И.З., Иксанова Д.Ф., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Малиевская Р.И., Авзалетдинова Д.Ш., Насретдинова Ю.Г., Урманова И.З., Иксанова Д.Ф.</copyright-holder><copyright-holder xml:lang="en">Malievskaya R.I., Avzaletdinova D.S., Nasretdinova I.G., Urmanova I.Z., Iksanova D.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://endofocus.elpub.ru/jour/article/view/96">https://endofocus.elpub.ru/jour/article/view/96</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Распространенность метаболического синдрома (МС) среди лиц с сахарным диабетом 1 типа (СД1) широко варьирует в зависимости от используемых критериев от 6,4 до 57%. Актуальность изучения МС при СД1 обусловлена высоким риском развития микро- и макрососудистых осложнений. Существующие в настоящее время критерии МС и споры по поводу включения СД1 в качестве его критерия не обеспечивают надежность в диагностике МС при данном заболевании.</p></sec><sec><title>Цель</title><p>Цель. Оценить распространенность МС у взрослых с СД1 и его влияние на течение заболевания.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Исследовано 134 пациента в возрасте старше 18 лет, в том числе 67 (50%) мужчин и 67 (50%) женщин. Медиана возраста составила 33 [19; 43] года, медиана длительности диабета – 13 [4; 27] лет. Наличие МС оценивалось по критериям совместного промежуточного заявления (Joint Interim Statement, JIS) 2009 г.</p></sec><sec><title>Результаты</title><p>Результаты. МС выявлен у 34 (25,4%) исследованных пациентов. Количество пациентов, не имеющих других критериев МС, за исключением СД1, составило 57 (42,5%), доля пациентов, имеющих 2 компонента МС (один из которых у всех – диабет), – 43 (32,1%). Показатели окружности талии &gt;94 см у мужчин и &gt; 80 см у женщин, а также артериального давления &gt; 130 и 85 мм рт. ст. были самыми частыми компонентами МС (73,5 и 70,6% соответственно). Фактор чувствительности к инсулину был значимо ниже в группе лиц с МС (р</p></sec><sec><title>Заключение</title><p>Заключение. МС является нередким состоянием при СД1, имеющим в своей основе инсулинорезистентность. Наличие МС связано с риском развития диабетической нефропатии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. The prevalence of metabolic syndrome (MS) among people with type 1 diabetes mellitus (T1DM) varies widely depending on the criteria used and ranges from 6.4 to 57%. The relevance of studying the MS in T1DM is caused by the high risk of developing of micro and macrovascular complications. The current criteria for MS and the controversy over the inclusion of T1DM as a criterion do not provide reliability in diagnosing MS in this disease.</p></sec><sec><title>The aim</title><p>The aim. To assess the prevalence of MS in adults with T1DM and its impact on the course of the disease.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A total of 134 patients over the age of 18 years were studied, including 67 (50%) men and 67 (50%) women. The median age was 33[19; 43] years, the median duration of diabetes was 13 [4; 27] years. MS was assessed according to the criteria of the 2009 Joint Interim Statement (JIS).</p></sec><sec><title>Results</title><p>Results. MS was detected in 34 (25.4%) patients. The number of patients who did not have other criteria for MS except for T1DM was 57 (42.5%), 43 (32.1%) patients had 2 components of MS (one of the components in all was diabetes). Waist circumference &gt;94 cm in men and &gt; 80 cm in women, as well as blood pressure &gt; 130 and 85 mm Hg were the most common components of MS (73.5 and 70.6% respectively). The insulin sensitivity coeﬃcient was signiﬁcantly lower in the group of people with MS (p=0.012). In patients with MS, only diabetic nephropathy was signiﬁcantly more common (p = 0.019), while the diﬀerences in the frequency of retinopathy and neuropathy were statistically insigniﬁcant.</p></sec><sec><title>Conclusion</title><p>Conclusion. MS is a common condition in T1DM, which is based on insulin resistance. Presence of MS is associated with a risk of developing of diabetic nephropathy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 1 типа</kwd><kwd>метаболический синдром</kwd><kwd>осложнения диабета</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 1 diabetes mellitus</kwd><kwd>metabolic syndrome</kwd><kwd>diabetic complications</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена по инициативе авторов без привлечения финансирования.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Alberti KG, Eckel RH, Grundy SM et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640–45. doi: 10.1161/CIRCULATIONAHA.109.192644.</mixed-citation><mixed-citation xml:lang="en">Alberti KG, Eckel RH, Grundy SM et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640–45. doi: 10.1161/CIRCULATIONAHA.109.192644.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Q, Yang D, Deng H et al. Association between metabolic syndrome and microvascular complications in Chinese adults with type 1 diabetes mellitus. Diabetes Metab J. 2022; 46(1): 93–103. doi: 10.4093/dmj.2020.0240.</mixed-citation><mixed-citation xml:lang="en">Huang Q, Yang D, Deng H et al. Association between metabolic syndrome and microvascular complications in Chinese adults with type 1 diabetes mellitus. Diabetes Metab J. 2022; 46(1): 93–103. doi: 10.4093/dmj.2020.0240.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Riaz A, Asghar S, Shahid S et al. Prevalence of metabolic syndrome and its risk factors influence on microvascular complications in patients with type 1 and type 2 diabetes mellitus. Cureus. 2024; 16(3): e55478. doi: 10.7759/cureus.55478.</mixed-citation><mixed-citation xml:lang="en">Riaz A, Asghar S, Shahid S et al. Prevalence of metabolic syndrome and its risk factors influence on microvascular complications in patients with type 1 and type 2 diabetes mellitus. Cureus. 2024; 16(3): e55478. doi: 10.7759/cureus.55478.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2021; 38(2): e14376. doi: 10.1111/dme.14376.</mixed-citation><mixed-citation xml:lang="en">Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2021; 38(2): e14376. doi: 10.1111/dme.14376.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Guo K, Zhang L, Ye J et al. Metabolic syndrome associated with higher glycemic variability in type 1 diabetes: A multicenter cross-sectional study in china. Front Endocrinol (Lausanne). 2022; 13: 972785. doi: 10.3389/fendo.2022.972785.</mixed-citation><mixed-citation xml:lang="en">Guo K, Zhang L, Ye J et al. Metabolic syndrome associated with higher glycemic variability in type 1 diabetes: A multicenter cross-sectional study in china. Front Endocrinol (Lausanne). 2022; 13: 972785. doi: 10.3389/fendo.2022.972785.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Colom C, Rull A, Sanchez-Quesada JL, Perez A. Cardiovascular disease in type 1 diabetes mellitus: Epidemiology and management of cardiovascular risk. J Clin Med. 2021; 10(8): 1798. doi: 10.3390/jcm10081798.</mixed-citation><mixed-citation xml:lang="en">Colom C, Rull A, Sanchez-Quesada JL, Perez A. Cardiovascular disease in type 1 diabetes mellitus: Epidemiology and management of cardiovascular risk. J Clin Med. 2021; 10(8): 1798. doi: 10.3390/jcm10081798.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lecumberri E, Nattero-Chavez L, Quinones Silva J et al. Impact of excluding hyperglycemia from international diabetes federation metabolic syndrome diagnostic criteria on prevalence of the syndrome and its association with microvascular complications, in adult patients with type 1 diabetes. Endocrine. 2022; 76(3): 601–11. doi: 10.1007/s12020-022-03041-8.</mixed-citation><mixed-citation xml:lang="en">Lecumberri E, Nattero-Chavez L, Quinones Silva J et al. Impact of excluding hyperglycemia from international diabetes federation metabolic syndrome diagnostic criteria on prevalence of the syndrome and its association with microvascular complications, in adult patients with type 1 diabetes. Endocrine. 2022; 76(3): 601–11. doi: 10.1007/s12020-022-03041-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Леонова Н.В., Чумакова Г.А., Цирикова А.В., Пушкарева С.В. Влияние метаболического синдрома на риск развития осложнений сахарного диабета типа 1. Российский кардиологический журнал. 2015; (4): 55–58. doi: 10.15829/1560-4071-2015-4-55-58.</mixed-citation><mixed-citation xml:lang="en">Леонова Н.В., Чумакова Г.А., Цирикова А.В., Пушкарева С.В. Влияние метаболического синдрома на риск развития осложнений сахарного диабета типа 1. Российский кардиологический журнал. 2015; (4): 55–58. doi: 10.15829/1560-4071-2015-4-55-58.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wallace AS, Chang AR, Shin JI et al. Obesity and chronic kidney disease in US adults with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2022; 107(5): 1247–56. doi: 10.1210/clinem/dgab927.</mixed-citation><mixed-citation xml:lang="en">Wallace AS, Chang AR, Shin JI et al. Obesity and chronic kidney disease in US adults with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2022; 107(5): 1247–56. doi: 10.1210/clinem/dgab927.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Genua I, Franch-Nadal J, Navas E et al. Obesity and related comorbidities in a large population-based cohort of subjects with type 1 diabetes in Catalonia. Front Endocrinol (Lausanne). 2022; 13: 1015614. doi: 10.3389/fendo.2022.1015614.</mixed-citation><mixed-citation xml:lang="en">Genua I, Franch-Nadal J, Navas E et al. Obesity and related comorbidities in a large population-based cohort of subjects with type 1 diabetes in Catalonia. Front Endocrinol (Lausanne). 2022; 13: 1015614. doi: 10.3389/fendo.2022.1015614.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2021; 38(2): e14376. doi: 10.1111/dme.14376.</mixed-citation><mixed-citation xml:lang="en">Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2021; 38(2): e14376. doi: 10.1111/dme.14376.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: A systematic review and meta-analysis. Diabetol Metab Syndr. 2021; 13(1): 25. doi: 10.1186/s13098-021-00641-8.</mixed-citation><mixed-citation xml:lang="en">Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: A systematic review and meta-analysis. Diabetol Metab Syndr. 2021; 13(1): 25. doi: 10.1186/s13098-021-00641-8.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Agrawal S, Ganie MA, Goyal A et al. Metabolic syndrome in patients with type 1 diabetes mellitus at a tertiary centre in North India: A ﬁve year follow up study. Diabetes Metab Syndr. 2023; 17(6): 102781. doi: 10.1016/j.dsx.2023.102781.</mixed-citation><mixed-citation xml:lang="en">Agrawal S, Ganie MA, Goyal A et al. Metabolic syndrome in patients with type 1 diabetes mellitus at a tertiary centre in North India: A ﬁve year follow up study. Diabetes Metab Syndr. 2023; 17(6): 102781. doi: 10.1016/j.dsx.2023.102781.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Guo K, Zhang L, Ye J et al. Metabolic syndrome associated with higher glycemic variability in type 1 diabetes: A multicenter cross-sectional study in china. Front Endocrinol (Lausanne). 2022; 13: 972785. doi: 10.3389/fendo.2022.972785.</mixed-citation><mixed-citation xml:lang="en">Guo K, Zhang L, Ye J et al. Metabolic syndrome associated with higher glycemic variability in type 1 diabetes: A multicenter cross-sectional study in china. Front Endocrinol (Lausanne). 2022; 13: 972785. doi: 10.3389/fendo.2022.972785.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sun H, Saeedi P, Karuranga S et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119. doi: 10.1016/j.diabres.2021.109119.</mixed-citation><mixed-citation xml:lang="en">Sun H, Saeedi P, Karuranga S et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119. doi: 10.1016/j.diabres.2021.109119.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lee YB, Han K, Kim B et al. High proportion of adult cases and prevalence of metabolic syndrome in type 1 diabetes mellitus population in Korea: A nationwide study. Diabetes Metab J. 2019; 43(1): 76–89. doi: 10.4093/dmj.2018.0048.</mixed-citation><mixed-citation xml:lang="en">Lee YB, Han K, Kim B et al. High proportion of adult cases and prevalence of metabolic syndrome in type 1 diabetes mellitus population in Korea: A nationwide study. Diabetes Metab J. 2019; 43(1): 76–89. doi: 10.4093/dmj.2018.0048.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ferreira-Hermosillo A, Ibarra-Salce R, Rodriguez-Malacara J, Molina-Ayala MA. Comparison of indirect markers of insulin resistance in adult patients with Double Diabetes. BMC Endocr Disord. 2020 15; 20(1): 87. doi: 10.1186/s12902-020-00570-z.</mixed-citation><mixed-citation xml:lang="en">Ferreira-Hermosillo A, Ibarra-Salce R, Rodriguez-Malacara J, Molina-Ayala MA. Comparison of indirect markers of insulin resistance in adult patients with Double Diabetes. BMC Endocr Disord. 2020 15; 20(1): 87. doi: 10.1186/s12902-020-00570-z.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chillaron JJ, Flores-Le-Roux JA, Goday A et al. Síndrome metabólico y diabetes mellitus tipo 1: prevalencia y factores relacionados [Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors. Rev Esp Cardiol. 2010; 63(4): 423–29 (in Spanish)].</mixed-citation><mixed-citation xml:lang="en">Chillaron JJ, Flores-Le-Roux JA, Goday A et al. Síndrome metabólico y diabetes mellitus tipo 1: prevalencia y factores relacionados [Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors. Rev Esp Cardiol. 2010; 63(4): 423–29 (in Spanish)].</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
